Axon Enterprise
AXON
$390.29
-6.45%
Axon Enterprise builds a public safety operating system by integrating hardware — TASER conducted-energy devices, body cameras, in-car and fixed cameras, drones and counter-drone systems — with cloud software such as digital evidence management, training, and real-time situational awareness, operating within the Industrials sector under the Aerospace & Defense classification. The company is best understood as a platform incumbent rather than a pure hardware vendor: its TASER franchise and Evidence.com ecosystem create high switching costs and a recurring software attach rate that distinguishes it from traditional defense and law-enforcement suppliers. The current investor narrative is dominated by a sharp disconnect between operating momentum and share-price performance — Q2 2026 revenue grew roughly 35% year over year with a gross margin above 60%, and management has repeatedly raised long-term guidance on the back of AI-enabled products and drone demand, yet the stock has fallen more than 40% over the past year. Debate now centers on whether the September convertible-debt offering, which funds AI investment and acquisitions, represents prudent capital deployment or dilution risk, and on whether the company's heavy spending on R&D and stock-based compensation can be converted into durable GAAP earnings power.…
AXON
Axon Enterprise
$390.29
Related headlines
Investment Opinion: Should I buy AXON Today?
Rating: Hold. Axon's core thesis is a high-growth public safety platform with a sticky software ecosystem, but the current valuation (P/E of 355, P/S of 16.4) already prices in substantial future growth, and the stock's persistent downtrend (-40% over one year) reflects market skepticism. The analyst consensus is 'buy' with an average target of $690.68, implying 77% upside, but near-term risks from dilution and weak GAAP profitability warrant caution.
Supporting evidence includes revenue growth of 35.28% YoY in Q2 2026, gross margin above 60%, and a strong balance sheet (current ratio 2.53). However, net margin is only 4.49%, operating margin is negative, and free cash flow TTM is $133.2 million, which is modest relative to the $45.7 billion market cap. The forward P/E of 37.01 based on estimated EPS of $13.79 suggests that analysts expect significant earnings growth, but the company has yet to demonstrate consistent GAAP profitability. The implied upside to the average target is substantial, but the low target of $440 is only 12.7% above the current price, indicating limited downside support from analysts.
Key risks include dilution from convertible debt, competitive pressures, and the possibility of multiple compression if growth slows. The rating would upgrade to Buy if the stock price stabilizes and GAAP margins improve, or if revenue growth accelerates above 35% with positive operating leverage. It would downgrade to Sell if revenue growth decelerates below 20% or if operating margins fail to turn positive. Relative to its history and peers, AXON is overvalued on traditional metrics but may be fairly valued on a growth-adjusted basis if it can sustain its trajectory.
Sign up to view all
AXON 12-Month Price Forecast
Axon presents a compelling growth story with 35% revenue growth and a sticky software ecosystem, but the valuation is stretched and profitability is thin. The stock's 40% decline over the past year reflects these concerns, yet analyst targets remain far above current levels. The risk/reward is balanced: the bull case (30% probability) offers significant upside to $690-$830, while the bear case (20% probability) could see the stock fall to $339-$440. I would upgrade to bullish if the company demonstrates operating leverage and positive GAAP earnings, and downgrade to bearish if revenue growth decelerates or dilution accelerates.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Axon Enterprise's 12-month outlook, with a consensus price target around $690.68 and implied upside of +77.0% versus the current price.
Average Target
$690.68
0 analysts
Implied Upside
+77.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$440 - $830
Analyst target range
Drowning in data?
Find the real signal!
Bulls vs Bears: AXON Investment Factors
The bull case for Axon rests on its exceptional revenue growth (35% YoY), high-margin software attach, and a massive disconnect between analyst targets (average $690.68) and the current price ($390.29). The bear case centers on extreme valuation multiples (P/E of 355, P/S of 16.4), weak GAAP profitability (net margin 4.5%), and dilution from convertible debt. Currently, the bear evidence appears stronger in the near term, given the stock's persistent downtrend and negative momentum, but the bull case has substantial merit if growth continues and margins improve. The single most important tension is whether Axon can convert its rapid revenue growth into durable GAAP earnings power without further dilution, which would justify its premium valuation and close the gap to analyst targets.
Bullish
- Revenue growth accelerating at 35%: Q2 2026 revenue grew 35.28% year over year to $904.4 million, up from $668.5 million in Q2 2025. This acceleration from prior periods demonstrates robust demand for Axon's ecosystem of TASER devices, body cameras, and cloud software, with AI-enabled products and drones cited as key growth drivers.
- Analyst consensus strongly bullish: 19 analysts rate AXON a 'buy' with a mean recommendation of 1.67 (where 1 is strong buy). The average target price of $690.68 implies 77% upside from the current $390.29, and even the low target of $440 represents 12.7% upside, indicating broad confidence in the company's trajectory.
- High-margin software attach: Gross margin remains above 60% (60.42% in Q2 2026), reflecting the recurring software and services mix within the public safety operating system. This high-margin base provides operating leverage as revenue scales, despite current investments in R&D and acquisitions.
- Strong balance sheet and liquidity: Current ratio of 2.53 indicates ample short-term liquidity, and debt-to-equity of 0.59 is manageable. The September convertible debt offering, while initially spooking investors, provides capital for AI investment and acquisitions without immediate cash strain, supporting long-term growth initiatives.
Bearish
- Extreme valuation multiples: AXON trades at a trailing P/E of 354.96, price-to-sales of 16.43, and EV/EBITDA of 236.13, which are extraordinarily high even for a high-growth company. The PEG ratio is negative (-5.23) due to minimal GAAP earnings, raising concerns about the sustainability of such premiums if growth decelerates.
- Weak GAAP profitability: Despite strong revenue growth, net margin is only 4.49% and operating margin is -2.23%, with EPS of just $0.0027. Heavy spending on R&D ($208.7 million in Q2 2026) and stock-based compensation continues to pressure bottom-line results, and the company has yet to demonstrate durable GAAP earnings power.
- Convertible debt dilution risk: The September convertible debt offering, while providing capital for AI and acquisitions, raises dilution concerns. Shares outstanding have increased from 76.9 million in Q1 2025 to 80.4 million in Q2 2026, and further dilution could weigh on per-share metrics if the stock price remains depressed.
- Negative price momentum: The stock is down 6.45% on the latest day, 16.68% over the past month, and 23.51% over three months, with a relative strength versus the S&P 500 of -17.90% (1-month) and -55.69% (1-year). This persistent downtrend reflects negative market sentiment and could continue to pressure shares in the near term.
AXON Technical Analysis
Beta
1.44
1.44x market volatility
Max Drawdown
-55.5%
Largest decline past year
52-Week Range
$339-$764
Price range past year
Annual Return
-40.2%
Cumulative gain past year
| Period | AXON Return | S&P 500 |
|---|---|---|
| 1m | -16.7% | +0.2% |
| 3m | -23.5% | +2.9% |
| 6m | -3.1% | +8.4% |
| 1y | -40.2% | +14.9% |
| ytd | -30.7% | +11.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AXON Fundamental Analysis
Quarterly Revenue
$904389000.0B
2026-06
Revenue YoY Growth
+35.3%
YoY Comparison
Gross Margin
60.4%
Latest Quarter
Free Cash Flow
$133192000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AXON Overvalued?
PE
355.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 32x~287x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
236.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant. Axon's GAAP profitability is thin, with a net margin of 4.49% and operating margin of -2.23%, despite a 60.42% gross margin. The company's heavy investment in R&D ($208.7 million in Q2 2026, up from $162.6 million a year earlier) and stock-based compensation continues to pressure earnings. Additionally, the September convertible debt offering increases leverage (debt-to-equity of 0.59) and potential dilution, with shares outstanding rising from 76.9 million to 80.4 million over the past year. Free cash flow is positive at $133.2 million TTM but relatively low compared to the $45.7 billion market cap, highlighting the need for continued growth to justify valuation.
Market and competitive risks are pronounced. AXON trades at a trailing P/E of 354.96 and P/S of 16.43, leaving little room for error; any growth deceleration could trigger severe multiple compression. The stock's beta of 1.44 indicates higher volatility than the market, and with the S&P 500 up 15.53% over the past year while AXON is down 40.16%, relative strength is deeply negative. Competitive threats are emerging, as evidenced by MSI's $139 million public safety contract win in Louisiana, and regulatory scrutiny over TASER devices and data privacy could increase. Macro factors, such as rising geopolitical tensions and higher yields, disproportionately impact high-multiple growth stocks.
The worst-case scenario involves a combination of slowing revenue growth, margin compression, and failed AI investments, leading to a sharp de-rating. The 52-week low is $339.01, representing a 13.1% decline from the current $390.29. However, the maximum drawdown over the past year is -55.51%, indicating that a more severe sell-off could occur if sentiment deteriorates further. In a bear case, the stock could retest the 52-week low or fall to the analyst low target of $440 (which is above the current price, so the downside is limited to the 52-week low). Realistically, an investor could lose 13% to the 52-week low, but a broader market correction or company-specific miss could drive a 30-40% decline from current levels.
FAQ
The key risks include: 1) Valuation risk: extreme multiples (P/E 355) leave little room for error; 2) Profitability risk: net margin of 4.49% and operating margin of -2.23% mean the company is barely profitable on a GAAP basis; 3) Dilution risk: the convertible debt offering could lead to further share issuance, with shares already up from 76.9 million to 80.4 million; 4) Competitive risk: MSI and others are winning large public safety contracts, and regulatory scrutiny could increase. These risks are ranked from highest to lowest severity, with valuation and profitability being the most immediate concerns.
Our 12-month forecast has three scenarios: Bull (30% probability) with a target range of $690-$830, Base (50%) at $440-$690, and Bear (20%) at $339-$440. The base case is most likely, assuming revenue growth moderates to 25-30% and margins improve slightly. The key assumption is that Axon continues to grow revenue at a healthy pace while gradually improving profitability. The average analyst target of $690.68 aligns with our base case upper bound, while the low target of $440 provides support.
AXON is overvalued on traditional metrics: trailing P/E of 354.96, P/S of 16.43, and EV/EBITDA of 236.13. These multiples are far above the broader market and even many high-growth peers. However, the forward P/E of 37.01 based on estimated EPS of $13.79 suggests that analysts expect earnings to grow substantially. The market is pricing in high growth expectations, and any disappointment could lead to multiple compression. Relative to its own history, the stock is near the lower end of its valuation range after the recent sell-off, but still expensive on absolute terms.
AXON is a high-risk, high-reward investment. The stock trades at $390.29, down 40% over the past year, with a P/E of 355 and P/S of 16.4, which is expensive. However, revenue is growing at 35% YoY, and analysts have a 'buy' rating with an average target of $690.68, implying 77% upside. The biggest downside risk is a retest of the 52-week low of $339.01, a 13% decline. For long-term investors comfortable with volatility and a 3-5 year horizon, AXON could be a good buy on further weakness, but near-term risks from dilution and margin pressure suggest waiting for a better entry point.
AXON is more suitable for long-term investment given its high growth trajectory and volatile stock price (beta 1.44). The company does not pay a dividend, so returns depend entirely on capital appreciation. Short-term trading is risky due to the stock's sharp swings (e.g., -6.45% in one day) and negative momentum. A minimum holding period of 3-5 years is recommended to allow the company to execute on its growth strategy and for valuation to normalize. Earnings visibility is moderate, with analysts expecting EPS of $13.79 next year, but the path to sustained GAAP profitability remains uncertain.
